Diaceutics (DXRX)

Sector:

Health Care

Index:

FTSE AIM All-Share

107.00p
   
  • Change Today:
      3.00p
  • 52 Week High: 109.00
  • 52 Week Low: 80.50
  • Currency: UK Pounds
  • Shares Issued: 84.68m
  • Volume: 89,685
  • Market Cap: £90.61m
  • RiskGrade: 196

Diaceutics wins data deal with unnamed pharma firm

By Josh White

Date: Thursday 01 Apr 2021

LONDON (ShareCast) - (Sharecast News) - Diaceutics has secured a data licensing agreement with an unnamed global pharmaceutical company to provide Covid-19 testing data insights in the US, it announced on Thursday, enabled by its proprietary diagnostic network 'DXRX'.
The AIM-traded company said that with around 400 treatments for the coronavirus now in development, the contract win- which came as a result of insights made available by its recent algorithmic development of a Covid-19 diagnostic disease pathway (DDP) - showed the group was in a position to address the "imminent opportunity" presented by the Covid-19 treatment market.

It said the details of the contract, including the identity of the pharmaceutical company and the value, were confidential, and no further information could be disclosed.

The board did say that the contract value did not change management expectations of performance for the current financial year.

"We are delighted to be able to facilitate access to this valuable Covid-tested patient cohort," said chief executive officer Peter Keeling.

"This first Covid-19 data-licensing agreement for the company provides testing data insights and analytics to pharmaceutical companies actively developing treatments for the disease.

"With hundreds of Covid-19 treatments now in development to address a pandemic at global scale, it is critically important that pharmaceutical companies lean in towards digital testing solutions such as those enabled by DXRX, to ensure that they have the data insights, and testing infrastructure required to get patients tested and treated."

At 1503 BST, shares in Diaceutics were up 1.57% at 103.6p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Diaceutics Market Data

Currency UK Pounds
Share Price 107.00p
Change Today 3.00p
% Change 2.88 %
52 Week High 109.00
52 Week Low 80.50
Volume 89,685
Shares Issued 84.68m
Market Cap £90.61m
RiskGrade 196

Diaceutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
90.87% below the market average90.87% below the market average90.87% below the market average90.87% below the market average90.87% below the market average
81.25% below the sector average81.25% below the sector average81.25% below the sector average81.25% below the sector average81.25% below the sector average
Price Trend
45.03% above the market average45.03% above the market average45.03% above the market average45.03% above the market average45.03% above the market average
56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average56.76% above the sector average
Income Not Available
Growth
2.91% above the market average2.91% above the market average2.91% above the market average2.91% above the market average2.91% above the market average
16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average

Diaceutics Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 457 @ 107.00p
16:35 457 @ 107.00p
13:37 18,918 @ 104.50p
14:00 82 @ 104.00p
14:00 82 @ 104.00p

Diaceutics Key Personnel

CEO Ryan Gerard Keeling
CFO Nick Roberts

Top of Page